Sonnest, Inc.

Sonnest, Inc. is a pre-clinical healthcare company on a mission to revolutionize cardiac care with its innovative technology. The company's flagship product, Electrast™, is an ultrasound imaging drug designed to circulate through the body in an inactive state, selectively activating in the myocardium. This unique approach allows for quick and cost-effective evaluation of heart perfusion without the need for ionizing radiation or toxic dyes. The technology, developed by a talented team of cardiologists and chemical engineers at Drexel University, received grant funding from the Coulter-Drexel Program. The inventors partnered with a team of successful serial healthcare entrepreneurs with over 15 years of experience across multiple companies to form Sonnest, Inc. Founded in 2019, the company operates in the Health Care industry and is headquartered in the United States. The latest investment, a Convertible Note investment, was secured on 02 February 2022 from the Texas Halo Fund. Sonnest, Inc. aims to drive significant advancements in cardiac care and is poised to make a significant impact in the field of healthcare technology.